View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
May 27, 2021

Trulicity.com has the highest traffic in the type 2 diabetes digital space in the US

Among type 2 diabetes (T2D) patient websites, Eli Lilly's trulicity.com has the highest US engagement.

By GlobalData Healthcare

According to GlobalData’s Digital Spotlight: Top Digital Assets in Type 2 Diabetes (T2D) report, Eli Lilly’s trulicity.com website has the highest total traffic in the US among non-insulin T2D patient websites. The number of visitors to the site peaked last July, followed by this March (Figure 1).

This is in line with Eli Lilly’s high investment into paid keywords and digital display advertising for Trulicity (dulaglutide). The top five non-insulin T2D-branded patient websites by traffic included in this analysis were sites for Eli Lilly’s Trulicity and Jardiance (empagliflozin), AstraZeneca’s Bydureon (exenatide) and Farxiga (dapagliflozin), and Novo Nordisk’s Ozempic (semaglutide).

Trulicity.com received 46% of total traffic for the top five T2D-branded websites. The site received a moderate average visit duration of around 50 seconds, however, and around 1.7 pages per visit (Table 1). Engagement metrics for Boehringer Ingelheim/Eli Lilly’s jardiance.com are the highest, with the most time spent on the website (around two minutes), a low bounce rate of 70% and an average of two pages per visit, indicating a highly engaged audience.

Traffic to branded patient websites mostly originates from organic and paid searches (traffic sent via the results on search engines such as Google or Bing and search partners), followed by direct sources (traffic sent from users via a direct URL address entered into a browser, saved bookmarks or any links from outside the browser), and then from display advertisements. The traffic coming from social media sites was negligible.

Eli Lilly’s trulicity.com received much higher traffic from direct sources and display ads compared to the rest of the top five websites. Traffic to branded websites originating from paid search sources generally leads to a higher visit duration compared to the overall duration of the visits originating from other sources. Boehringer Ingelheim/Eli Lilly’s jardiance.com was an exception, as visitors spent less time on the site when visiting from paid search sources.

Novo Nordisk spent the most money on digital display advertising for Ozempic.com at around $6.2m over the past 12 months, followed by Eli Lilly’s trulicity.com at around $5m (Figure 2). All players invested in paid keywords. Eli Lilly invested significantly more than other players, with the number of paid keywords peaking last June with 2,600 keywords for Trulicity and totalling 13,500 keywords across 12 months. The second highest number of paid keywords came from AstraZeneca’s Farxiga, while AstraZeneca’s Bydureon and Boehringer Ingelheim/Eli Lilly’s Jardiance sites paid for the fewest keywords.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU